title: Biomarker-Driven Treatments Yield Better Results.
abstract: According to a meta-analysis of 351 phase I trials, choosing a therapy based on the abnormalities that drive a tumor yields higher response rates than therapeutic selections that aren't biomarker-driven.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D017321:Clinical Trials, Phase I as Topic; D018572:Disease-Free Survival; D006801:Humans; D015201:Meta-Analysis as Topic; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D057285:Precision Medicine; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor